|Videos|May 4, 2022
Urology Times 50 Innovations Series: Microsurgical testicular sperm extraction
Author(s)Urology Times staff
"Micro TESE is associated with higher sperm retrieval rates compared with conventional testicular sperm extraction, so this approach has really become the gold standard for sperm extraction in patients with non-obstructive azoospermia," says Denise Asafu-Adjei, MD, MPH.
Advertisement
Urology Times® is celebrating its 50th anniversary in 2022. To mark the occasion, we are highlighting 50 of the top innovations and developments that have transformed the field of urology over the past 50 years. In this installment, Denise Asafu-Adjei, MD, MPH, discusses the development of microsurgical testicular sperm extraction (microTESE). Asafu-Adjei is a urologist and medical director of male reproductive medicine at Loyola University, Chicago, Illinois.
Advertisement
Related to this article
William Huang, MD, discusses histotripsy for renal tumors, the #HOPE4KIDNEY trial, and the technology’s potential to preserve kidney function.
Systemic therapy now anchors MIBC care and expands bladder preservation options, according to Joshua J. Meeks, MD, PhD.
BCG optimization should precede checkpoint inhibitor intensification in BCG-naive high-risk NMIBC, according to Tom Jayram, MD.
Alicia Morgans, MD, discusses ARACOG findings on cognitive outcomes with darolutamide vs enzalutamide and the influence of genetic dementia risk.
The phase 1 study is intended to characterize the safety, tolerability, and feasibility of intravesical administration of UGN-501.
Elie Kaplan-Marans, MD, discusses geographic disparities in reproductive urology access and how work force gaps may affect comprehensive infertility evaluations.
Aaron Berger, MD, discusses patient selection for ARPI treatment holidays, monitoring during interruptions, and the role of testosterone recovery in interpreting PSA kinetics.
Paras H. Shah, MD, recaps data on emerging agents in high-risk NMIBC from the 2026 AUA North Central Section Meeting.
Advertisement
Advertisement
Trending on Urology Times
1
UGN-501 enters phase 1 testing for recurrent non–muscle invasive bladder cancer
2
Alicia Morgans, MD, discusses cognitive outcomes with darolutamide vs enzalutamide
3
Treating MIBC as a systemic disease reshapes bladder preservation
4
Infertility care: Examining geographic gaps in access
5